Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $3.299M Beat $1.405M Estimate

Author: Benzinga Newsdesk | November 06, 2025 07:24am
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $3.299 million which beat the analyst consensus estimate of $1.405 million by 134.76 percent. This is a 24.09 percent decrease over sales of $4.346 million the same period last year.

Posted In: ACRS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist